China's pharmaceutical industry is rapidly developing and accelerating significantly in the field of GLP-1 drugs.[1] An example is Jiangsu Hengrui Pharmaceuticals, one of China's largest firms, which has developed a new-generation injectable slimming drug based on the blood sugar and appetite-regulating hormone GLP-1.[1] Kailera's startup has acquired licenses from China, skipping years of research, and is planning a phase three clinical trial in the US with the goal of launching in 2030 or earlier.[1] This drug could outperform competitors in early and mid-stage trials.[1] The market for GLP-1 therapies will exceed $200 billion by 2031.[2] Lilly had $550 million in year-end inventory of the oral GLP-1 drug orforglipron, although it has not been approved.[1] Novo Nordisk plans to launch oral semaglutide for the treatment of obesity in 2026.[2]